Estados Unidos · Bolsa y Finanzas · CNBC

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Publicado por CNBC · Estados Unidos hace 39 min

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Leer el artículo completo en CNBC Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbc.com)

También te puede interesar

Energy's inverse grip on stock market hits a record high

Nvidia hits record close, nears unprecedented $6 trillion valuation

Mash-Up of Paramount and Warner Bros. Will Be Called Skydance

Business Insider

Data centers and healthcare were bright spots in the rough September jobs report

It’s not AI anymore, it’s ‘super intelligence’ (according to the White House)

Once a $2.3 Billion Network, Ethereum Layer-2 Blast Is Shutting Down